Minor Histocompatibility Antigen UTY as Target for Graft-versus-Leukemia and Graft-versus-Haematopoiesis in the Canine Model

Scandinavian Journal of Immunology

Volumn 77, Issue 1, 2013, Pages 39-53

  Bund, D ^a,b   Buhmann, R ^a,b   Gokmen F ^a,b   Zorn, J ^a,b   Kolb, H J ^a,b   Schmetzer, H M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; TETRATRICOPEPTIDE REPEAT PROTEIN; UNCLASSIFIED DRUG; UTY PEPTIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOG; FEMALE; GRAFT VERSUS HEMATOPOEISIS; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIESIS; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN TARGETING; T CELL LEUKEMIA; T LYMPHOCYTE ACTIVATION; Y CHROMOSOME;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; DOGS; FEMALE; GRAFT VS LEUKEMIA EFFECT; H-Y ANTIGEN; HEMATOPOIESIS; HUMANS; MALE; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84871685242     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12011     Document Type: Article

References (73)

1. Schmid C, Labopin M, Nagler A et al. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2012;119:1599-606.
2. Bleakley M, Riddell SR. Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol Cell Biol 2011;89:396-407.
3. Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 2001;7:789-94.
4. Jiang YZ, Mavroudis DA, Dermime S, Molldrem J, Hensel NF, Barrett AJ. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus- host disease. Bone Marrow Transplant 1997;19:899-903.
5. Michálek J, Collins RH, Hill BJ, Brenchley JM, Douek DC. Identification and monitoring of graft-versus-host specific T cell clone in stem cell transplantation. Lancet 2003;361:1183-5.
6. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008;112:4371-83.
7. Stern M, Ruggeri L, Mancusi A et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008;112:2990-5.
8. Ofran Y, Kim HT, Brusic V et al. Diverse patterns of T cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res 2010;16:1642-51.
9. Skaletsky H, Kuroda-Kawaguchi T, Minx PJ et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature 2003;423:825-37.
10. Mutis T, Goulmy E. Hematopoietic system specific antigens as targets for cellular immunotherapy of hematological malignancies. Semin Hematol 2002;39:23-31.
11. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. PNAS 1999;96:8639-44.
12. Warren EH, Gavin MA, Simpson E et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol 2000;164:2807-14.
13. Xiang Y, Zhu Z, Han G, Lin H, Xu L, Chen CD. JMJD3 is a histone H3K27 demethylase. Cell Res 2007;17:850-7.
14. Agger K, Cloos PA, Christensen J et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 2007;449:731-4.
15. Lan F, Bayliss PE, Rinn JL et al. A histone H3 lysine 27 demethylase regulates animal posterior development. Nature 2007;449:689-94.
16. Barbe L, Lundberg E, Oksvold P et al. Toward a confocal subcellular atlas of the human proteome. Mol Cell Proteomics 2008;7:499-508.
17. Xu J, Deng X, Watkins R, Disteche CM. Sex-specific differences in expression of histone demethylases Utx and Uty in mouse brain and neurons. J Neurosci 2008;28:4521-7.
18. Ivanov R, Hol S, Aarts T, Hagenbeek A, Slager EH, Ebeling S. UTY-specific TCR-transfer generates potential graft-versus-leukemia effector T cells. Br J Haematol 2005;129:392-402.
19. Vogt MH, Goulmy E, Kloosterboer FM et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T cell recognition. Blood 2000;96:3126-32.
20. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004;103:767-76.
21. Kolb HJ, Gunter W, Schumm M, Holler E, Wilmanns W, Thierfelder S. Adoptive immunotherapy in canine chimeras. Transplantation 1997;63:430-6.
22. Garden OA, Pinheiro D, Cunningham F. All creatures great and small: regulatory T cells in mice, humans, dogs and other domestic animal species. Int Immunopharmacol 2011;11:576-88.
23. Santos PS, Kellermann T, Uchanska-Ziegler B, Ziegler A. Genomic architecture of MHC-linked odorant receptor gene repertoires among 16 vertebrate species. Immunogenetics 2010;62:569-84.
24. Yuhki N, Beck T, Stephens R, Neelam B, O'Brien SJ. Comparative genomic structure of human, dog, and cat MHC: HLA, DLA, and FLA. J Hered 2007;98:390-9.
25. Baker SM, Karlsson L, Thurmond RL. Cloning, expression, purification, and activity of dog (Canis familiaris) and monkey (Saimiri boliviensis) cathepsin S. Protein Expr Purif 2003;28:93-101.
26. den Haan JM, Bontrop RE, Pool J et al. Conservation of minor histocompatibility antigens between human and non-human primates. Eur J Immunol 1996;26:2680-5.
27. Furlong RF, Yang Z. Diversifying and purifying selection in the peptide binding region of DRB in mammals. J Mol Evol 2008;66:384-94.
28. Takeshima SN, Sarai A, Saitou N, Aida Y. MHC class II DR classification based on antigen-binding groove natural selection. Biochem Biophys Res Commun 2009;385:137-42.
29. van der Feltz MJ, van der Korput HA, Giphart MJ, Westbroek DL. Dog MHC class I antigens contain beta 2-microglobulin. Exp Clin Immunogenet 1984;1:56-9.
30. Wieles B, Pool J, Wilke M et al. The diallelic locus encoding the minor histocompatibility antigen HA-1 is evolutionarily conserved. Tissue Antigens 2006;68:62-5.
31. Graumann MB, DeRose SA, Ostrander EA, Storb R. Polymorphism analysis of four canine MHC class I genes. Tissue Antigens 1998;51:374-81.
32. Wagner JL, Palti Y, DiDario D, Faraco J. Sequence of the canine major histocompatibility complex region containing non-classical class I genes. Tissue Antigens 2005;65:549-55.
33. Wagner JL, Burnett RC, DeRose SA, Francisco LV, Storb R, Ostrander EA. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation 1996;62:876-7.
34. Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985;21:235-46.
35. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9.
36. van der Bruggen P, Bastin J, Gajewski T et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994;24:3038-43.
37. Würtzen PA, Claesson MH. A HLA-A2-restricted human CTL line recognizes a novel tumor cell expressed p53 epitope. Int J Cancer 2002;99:568-72.
38. Nijman HW, Houbiers JG, Vierboom MP et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 1993;23:1215-9.
39. Bund D, Buhmann R, Gökmen F et al. Canine Dendritic cells using different serum-free methods as an approach to provide an animal model for immunotherapeutic strategies. Cell Immunol 2010;263:88-98.
40. Bund D, Mayr C, Kofler DM, Hallek M, Wendtner CM. Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8 + T cells. Exp Hematol 2006;34:860-9.
41. Scheibenbogen C, Romero P, Rivoltini L et al. Quantitation of antigen-reactive T cells in peripheral blood by IFNγ-ELISPOT assay and chromiumale-release assay: a four-centre comparative trial. J Immunol Methods 2000;244:81-9.
42. Karanikas V, Soukou F, Kalala F et al. Baseline levels of CD8 + T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals. Clin Immunol 2008;129:230-40.
43. Schmetzer H, Schmid C. Bookchapter: Part 1: 'Basic Aspects of Stem Cell Transplantation: Chapter 4. The T cells' role in anti-leukaemic reactions - perspectives for future therapies. In: Demirer T, ed. New Advances in Stem Cell Transplantation, Manhatten, NY: InTech, 2012: 959-82. ISBN 978-953-51-0013-3.
44. de Bueger M, Bakker A, van Rood JJ, Van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992;149:1788-94.
45. Voogt PJ, Goulmy E, Fibbe WE, Veenhof WF, Brand A, Falkenburg JH. Minor histocompatibility antigen H-Y is expressed on human hematopoietic progenitor cells. J Clin Invest 1988;82:906-12.
46. Kawasaki-Nishi S, Yamaguchi A, Forgac M, Nishi T. Tissue specific expression of the splice variants of the mouse vascuolar proton-translocating ATPase a4 subunit. Biochem Biophys Res Commun 2007;364:1032-6.
47. Sala P, Tonutti E, Feruglio C, Florian F, Colombatti A. Persistent expansions of CD4 + CD8 + peripheral blood T cells. Blood 1993;82:1546-52.
48. Ehrmann IE, Ellis PS, Mazeyrat S et al. Characterization of genes encoding translation initiation factor eIFEMALE-2gamma in mouse and human: sex chromosome localization, escape from X-inactivation and evolution. Hum Mol Genet 1998;7:1725-37.
49. Laaser I, Theis FJ, de Angelis MH, Kolb HJ, Adamski J. Huge Splicing Frequency in Human Y Chromosomal UTY Gene. OMICS 2011;15:141-54.
50. Shen P, Wang F, Underhill PA et al. Population genetic implications from sequence variation in four Y chromosome genes. PNAS 2000;97:7354-9.
51. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998;91:2197-207.
52. Dickinson AM, Wang XN, Sviland L et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002;8:410-4.
53. Kalhs P, White JS, Gervassi A, Storb R, Bean MA. In vitro recall of proliferative and cytolytic responses to minor histocompatibility antigens by dendritic cell enriched canine peripheral blood mononuclear cells. Transplantation 1995;59:112-8.
54. NCBI, National Center for Biotechnology Information [database online]. UTY tetratricopeptide repeat protein [Canis lupus familiaris], Protein ID: AAS92205.
55. Greenfield A, Scott D, Pennisi D et al. An H-YDb epitope is encoded by a novel mouse Y chromosome gene. Nat Genet 1996;14:474-8.
56. Apoil P, Blancher A. Sequences and evolution of mammalian RH gene transcripts and proteins. Immunogenetics 1999;49:15-25.
57. Barbosa-De-Deus R, Dos Mares-Guia ML, Nunes AZ et al. Leishmania major-like antigen for specific and sensitive serodiagnosis of human and canine visceral leishmaniasis. Clin Diagn Lab Immunol 2002;9:1361-6.
58. Biondo AW, Wiedmeyer CE, Sisson DD, Solter PF. Comparative sequences of canine and feline endothelin-1. Vet Clin Pathol 2003;32:188-94.
59. Campbell BG, Jabbes M. Canine and feline trefoil factor family peptides: highly conserved molecules with some unique characteristics. Res Vet Sci 2008;85:68-73.
60. Gold JS, Ferrone CR, Guevara-Patino JA et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003;170:5188-94.
61. Gyorffy S, Rodriguez-Lecompte JC, Woods JP et al. Bone marrowderived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J Vet Intern Med 2005;19:56-63.
62. Liao JC, Gregor P, Wolchok JD et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006;6:8.
63. Ollier WE, Kennedy LJ, Thomson W et al. Dog MHC alleles containing the human RA shared epitope confer susceptibility to canine rheumatoid arthritis. Immunogenetics 2001;53:669-73.
64. Scurrell E, Stanley R, Schöniger S. Immunohistochemical detection of NOD1 and NOD2 in the healthy murine and canine eye. Vet Ophthalmol 2009;12:269-75.
65. Sulaimon S, Kitchell B, Ehrhart E. Immunohistochemical detection of melanoma-specific antigens in spontaneous canine melanoma. J Comp Pathol 2002;127:162-8.
66. Valentini F, Tasca S, Gavazza A, Lubas G. Use of CD9 and CD61 for the characterization of AML-M7 by flow cytometry in a dog (*). Vet Comp Oncol 2012;10:312-8.
67. Zhang J, Chen X, Kent MS, Rodriguez CO, Chen X. Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor. Mol Cancer Res 2009;7:67-78.
68. Zhang L. Adaptive evolution and frequent gene conversion in the brain expressed X-linked gene family in mammals. Biochem Genet 2008;46:293-311.
69. Kolb HJ, Mittermüller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5.
70. Kolb HJ, Schattenberg A, Goldman JM et al. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor-lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-50.
71. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999;93:2336-41.
72. Georges GE, Lesnikova M, Storb R, Yunusov M, Little MT, Nash RA. Minor histocompatibility antigen-specific cytotoxic T lymphocytes generated with dendritic cells from DLA-identical littermates. Biol Blood Marr Transplant 2003;9:234-42.
73. Weber M, Lange C, Günther W, Franz M, Kremmer E, Kolb HJ. Minor histocompatibility antigens on canine hematopoietic progenitor cells. J Immunol 2003;170:5861-8.